Ligand Pharmaceuticals Incorporated (LGND)
Largest Insider Buys in Sector
LGND Stock Price History Chart
LGND Stock Performance
About Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; and Nexterone, a captisol-enabled formulation of amiodarone; and Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Bryxta and Zybev for various indications; and Minnebro for the treatment of hypertension. The company's partners and licenses programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver and kidney disease, and other diseases. Further, it sells Captisol materials. The company was incorporated in 1987 and is headquartered in Emeryville, California.
Insider Activity of Ligand Pharmaceuticals Incorporated
Over the last 12 months, insiders at Ligand Pharmaceuticals Incorporated have bought $237,529 and sold $3.7M worth of Ligand Pharmaceuticals Incorporated stock.
On average, over the past 5 years, insiders at Ligand Pharmaceuticals Incorporated have bought $222,219 and sold $3.29M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Davis Todd C (CHIEF EXECUTIVE OFFICER) — $475,058.
The last purchase of 4,000 shares for transaction amount of $237,529 was made by Davis Todd C (CHIEF EXECUTIVE OFFICER) on 2023‑09‑22.
List of Insider Buy and Sell Transactions, Ligand Pharmaceuticals Incorporated
| 2024-05-17 | Sale | Espinoza Octavio | Chief Financial Officer | 5,156 0.0289% | $86.66 | $446,844 | -5.31% | |
| 2024-05-16 | Sale | Espinoza Octavio | Chief Financial Officer | 2,264 0.0126% | $86.00 | $194,712 | -3.50% | |
| 2024-05-15 | Sale | Espinoza Octavio | Chief Financial Officer | 5,873 0.0328% | $86.01 | $505,148 | -3.96% | |
| 2024-05-14 | Sale | Korenberg Matthew E | President & Chief Operating | 14,158 0.0786% | $85.10 | $1.2M | -2.84% | |
| 2024-05-13 | Sale | Korenberg Matthew E | President & Chief Operating | 3,440 0.0193% | $84.54 | $290,828 | -0.69% | |
| 2024-05-09 | Sale | Reardon Andrew | Chief Legal Officer & | 10,000 0.0537% | $83.04 | $830,449 | -2.70% | |
| 2024-05-09 | Sale | Gray Nancy Ryan | director | 934 0.005% | $83.20 | $77,713 | -2.70% | |
| 2024-03-05 | Sale | Sabba Stephen L | director | 1,893 0.0108% | $74.30 | $140,650 | +7.21% | |
| 2024-02-28 | Sale | Espinoza Octavio | Chief Financial Officer | 140 0.0008% | $88.46 | $12,384 | -6.38% | |
| 2023-09-22 | Davis Todd C | CHIEF EXECUTIVE OFFICER | 4,000 0.0232% | $59.38 | $237,529 | +22.49% | ||
| 2023-05-16 | Sale | KOZARICH JOHN W | director | 4,444 0.0261% | $77.20 | $343,081 | -8.93% | |
| 2023-05-10 | Sale | Sabba Stephen L | director | 6,408 0.0373% | $77.13 | $494,225 | -9.46% | |
| 2023-05-08 | Sale | KOZARICH JOHN W | director | 6,408 0.0371% | $76.56 | $490,628 | -9.30% | |
| 2023-03-24 | Sale | Reardon Andrew | See Remarks | 300 0.0018% | $69.92 | $20,977 | +2.19% | |
| 2022-12-16 | Sale | HIGGINS JOHN L | director | 10,000 0.0585% | $61.87 | $618,657 | +9.29% | |
| 2022-11-17 | Sale | HIGGINS JOHN L | Chief Executive Officer | 10,000 0.0593% | $78.32 | $783,173 | -11.04% | |
| 2022-11-09 | Sale | Espinoza Octavio | Chief Financial Officer | 1,696 0.0101% | $75.64 | $128,283 | -6.95% | |
| 2022-05-13 | FOEHR MATTHEW W | President and COO | 2,500 0.0143% | $82.76 | $206,910 | +21.81% | ||
| 2018-10-08 | Sale | Davis Todd C | director | 2,500 0.0122% | $253.99 | $634,978 | -52.26% | |
| 2018-10-01 | Sale | FOEHR MATTHEW W | President and COO | 12,000 0.0573% | $273.88 | $3.29M | -56.27% |
Insider Historical Profitability
| Davis Todd C | CHIEF EXECUTIVE OFFICER | 73090 0.4192% | $77.82 | 2 | 7 | +24.73% |
| Sabba Stephen L | director | 28926 0.1479% | $77.82 | 3 | 6 | +53.3% |
| Reardon Andrew | See Remarks | 22205 0.0935% | $77.82 | 0 | 2 | |
| Espinoza Octavio | Chief Financial Officer | 23379 0.0508% | $77.82 | 0 | 5 | |
| Korenberg Matthew E | EVP,Finance & Strategy and CFO | 86263 0.0387% | $77.82 | 0 | 4 | |
| Gray Nancy Ryan | director | 5633 0.0314% | $77.82 | 0 | 1 | |
| Loeb Daniel S | 2027378 11.6275% | $77.82 | 2 | 1 | <0.0001% | |
| HIGGINS JOHN L | director | 422984 2.4259% | $77.82 | 7 | 25 | +13.79% |
| FOEHR MATTHEW W | President and COO | 173354 0.9942% | $77.82 | 7 | 13 | +42.46% |
| BVF PARTNERS L P/IL | 130175 0.7466% | $77.82 | 42 | 13 | +48.5% | |
| MEGLASSON MARTIN | V-P, Discovery Research | 102250 0.5864% | $77.82 | 4 | 1 | <0.0001% |
| MAIER PAUL V | Sr. V-P, CFO | 78251 0.4488% | $77.82 | 0 | 7 | |
| KNOTT DAVID M | director | 66152 0.3794% | $77.82 | 29 | 24 | +12.84% |
| Aryeh Jason | director | 51392 0.2947% | $77.82 | 16 | 27 | +22.85% |
| KOZARICH JOHN W | director | 38488 0.2207% | $77.82 | 11 | 15 | +5.21% |
| Dziewanowska Zofia E | VP, Clinical Research | 33977 0.1949% | $77.82 | 0 | 1 | |
| Berkman Charles S | SVP, Gen. Counsel & Secretary | 27763 0.1592% | $77.82 | 4 | 14 | +29.71% |
| Patel Sunil | director | 24524 0.1407% | $77.82 | 4 | 2 | +36.17% |
| JOHNSON IRVING S | director | 22929 0.1315% | $77.82 | 0 | 2 | |
| DeSilva Nishan M | VP, Finance & Strategy and CFO | 22282 0.1278% | $77.82 | 1 | 4 | +51.07% |
| LAMATTINA JOHN L | director | 21449 0.123% | $77.82 | 1 | 5 | +21.14% |
| Sharp John P | VP Finance and CFO | 17667 0.1013% | $77.82 | 0 | 5 | |
| Kazmi Syed | VP, Bus. Dev. & Strategic Plan | 14230 0.0816% | $77.82 | 0 | 2 | |
| ROCCA MICHAEL A | director | 8000 0.0459% | $77.82 | 0 | 1 | |
| NEGRO-VILAR ANDRES | Exe V-P, R & D, CSO | 7233 0.0415% | $77.82 | 0 | 3 | |
| CROSS ALEXANDER D | director | 6001 0.0344% | $77.82 | 0 | 3 | |
| GROVES ERIC S | V-P, Project Management | 5127 0.0294% | $77.82 | 0 | 1 | |
| Herman Melanie J | Director of Accounting | 3297 0.0189% | $77.82 | 2 | 6 | +28.79% |
| PETTTIT WILLIAM A | Sr. V-P, HR and Administration | 889 0.0051% | $77.82 | 0 | 3 | |
| CROUCH TAYLOR | Sr. V-P, Ops & Pres. Int'l | 0 0% | $77.82 | 0 | 1 | |
| ELAN CORP PLC | 10 percent owner | 0 0% | $77.82 | 0 | 2 | |
| LITALIEN JAMES J | Sr. V-P, Reg Affairs & Comp. | 0 0% | $77.82 | 0 | 3 | |
| BROADDUS WARNER R | V-P, Gen. Counsel & Secy. | 0 0% | $77.82 | 0 | 2 |
Institutional Investor Ownership
| BlackRock | $209.67M | 15.97 | 2.87M | -3.17% | -$6.87M | 0.01 | |
| The Vanguard Group | $137.73M | 10.49 | 1.88M | +0.41% | +$555,413.80 | <0.01 | |
| Macquarie Group | $75.53M | 5.75 | 1.03M | +4.64% | +$3.35M | 0.06 | |
| Janus Henderson | $73.72M | 5.61 | 1.01M | -24.92% | -$24.46M | 0.04 | |
| Stephens Investment Management Group LLC | $50.93M | 3.88 | 696,758 | +5.66% | +$2.73M | 0.68 | |
| State Street | $49.07M | 3.74 | 671,284 | +0.45% | +$219,300.00 | <0.01 | |
| Dimensional Fund Advisors | $48.54M | 3.7 | 664,081 | +0.42% | +$203,437.30 | 0.01 | |
| Cardinal Capital Management Llc Ct | $40.88M | 3.11 | 559,235 | +151.99% | +$24.66M | 2.08 | |
| Villere & Co. | $35.87M | 2.73 | 490,752 | +14.65% | +$4.58M | 2.93 | |
| Geode Capital Management | $27.85M | 2.12 | 380,970 | +2.74% | +$742,445.87 | <0.01 | |
| Standard Life | $20.58M | 1.57 | 281,556 | -3.05% | -$647,812.21 | 0.04 | |
| Rice Hall James & Associates, LLC | $20.45M | 1.56 | 279,784 | +1.37% | +$276,025.59 | 1.24 | |
| Impax Asset Management Group | $18.66M | 1.42 | 255,208 | +24.37% | +$3.66M | 0.07 | |
| Morgan Stanley | $18.41M | 1.4 | 251,897 | +26.46% | +$3.85M | <0.01 | |
| Deutsche Bank | $17.24M | 1.31 | 235,904 | +26.9% | +$3.66M | 0.01 | |
| Chicago Capital Llc | $16.78M | 1.28 | 229,596 | -0.83% | -$139,986.43 | 0.51 | |
| Invesco | $15.72M | 1.2 | 215,095 | +0.09% | +$14,181.40 | <0.01 | |
| Northern Trust | $15.37M | 1.17 | 210,286 | -4.32% | -$694,011.42 | <0.01 | |
| Ashford Capital Management Inc | $14.37M | 1.09 | 196,535 | New | +$14.37M | 1.95 | |
| William Blair Investment Management | $13.83M | 1.05 | 189,247 | +1.02% | +$139,255.50 | 0.04 | |
| Bank of America | $10.95M | 0.83 | 149,738 | +32.86% | +$2.71M | <0.01 | |
| Charles Schwab | $10.95M | 0.83 | 149,776 | -7.25% | -$855,562.43 | <0.01 | |
| BNY Mellon | $10.76M | 0.82 | 147,164 | -5.4% | -$613,672.65 | <0.01 | |
| Kornitzer Capital Management Inc Ks | $9.9M | 0.75 | 135,482 | 0% | +$0 | 0.18 | |
| Ziegler FAMCO Hedged Equity Fund | $9.76M | 0.74 | 133,567 | +164.89% | +$6.08M | 0.03 | |
| Ameriprise Financial | $8.5M | 0.65 | 116,293 | +9.12% | +$710,385.69 | <0.01 | |
| Allspring Global Investments | $6.23M | 0.47 | 85,195 | +129.19% | +$3.51M | 0.01 | |
| Dana Investment Advisors | $5.54M | 0.42 | 75,846 | New | +$5.54M | 0.19 | |
| Russell Investments Group Ltd | $5.35M | 0.41 | 73,161 | +155.25% | +$3.25M | 0.01 | |
| Man Group Plc | $5.02M | 0.38 | 68,657 | -52.47% | -$5.54M | 0.01 | |
| Nordea Investment Management Ab | $4.94M | 0.38 | 68,328 | -0.93% | -$46,443.89 | 0.01 | |
| D. E. Shaw & Co. | $4.58M | 0.35 | 62,592 | -28.8% | -$1.85M | 0.01 | |
| CastleArk Management, LLC | $4.53M | 0.35 | 61,913 | -1.26% | -$57,675.90 | 0.19 | |
| RhumbLine Advisers | $4.4M | 0.34 | 60,255 | +1.23% | +$53,362.71 | <0.01 | |
| Goldman Sachs | $4.17M | 0.32 | 57,111 | -10.59% | -$494,521.49 | <0.01 | |
| Acuitas Investments, LLC | $4M | 0.3 | 54,682 | +14.63% | +$510,164.87 | 2.1 | |
| Envestnet Asset Management Inc | $3.94M | 0.3 | 53,895 | +19.45% | +$641,452.58 | <0.01 | |
| Fisher Asset Management Llc | $3.9M | 0.3 | 53,377 | +8.28% | +$298,247.95 | <0.01 | |
| Baird Financial Group Inc | $3.82M | 0.29 | 52,310 | +32.51% | +$938,238.50 | 0.01 | |
| Ranger Investment Management L P | $3.76M | 0.29 | 51,450 | New | +$3.76M | 0.25 | |
| JPMorgan Chase | $3.66M | 0.28 | 50,006 | -20.47% | -$941,016.40 | <0.0001 | |
| Citadel Advisors LLC | $3.62M | 0.28 | 49,564 | +405.65% | +$2.91M | <0.01 | |
| Isthmus Partners, LLC | $3.53M | 0.27 | 48,331 | +40.71% | +$1.02M | 0.4 | |
| Legal & General | $3.48M | 0.27 | 47,622 | +0.31% | +$10,818.80 | <0.01 | |
| Renaissance Technologies | $3.44M | 0.26 | 47,100 | -28.96% | -$1.4M | 0.01 | |
| Hillsdale Investment Management Inc. | $3.29M | 0.25 | 45,032 | +8.43% | +$255,849.98 | 0.27 | |
| Nuveen | $3.15M | 0.24 | 43,037 | 0% | +$0 | <0.01 | |
| Uniplan Investment Counsel Inc | $3.01M | 0.23 | 41,201 | New | +$3.01M | 0.25 | |
| AMI Asset Management Corp. | $2.99M | 0.23 | 40,931 | -3.96% | -$123,393.91 | 0.15 | |
| GW&K Investment Management | $2.91M | 0.22 | 39,765 | -28.14% | -$1.14M | 0.03 |